A randomized, double-blind, placebo-controlled phase I clinical trial of rotavirus inactivated vaccine (Vero cell) in a healthy adult population aged 18-49 years to assess safety and preliminary observation of immunogenicity

被引：2

作者：

Wu, Jin-Yuan ^{[1
]}

Zhang, Wei ^{[2
]}

Pu, Jing ^{[1
]}

Liu, Yan ^{[3
]}

Huang, Li-Li ^{[2
]}

Zhou, Yan ^{[1
]}

Gao, Jia-Mei ^{[3
]}

Tan, Jie-Bing ^{[2
]}

Liu, Xin-Ling ^{[1
]}

Yang, Jing ^{[1
]}

Lin, Xiao-Chen ^{[1
]}

Feng, Guang-Wei ^{[2
]}

Yin, Na ^{[1
]}

Chen, Rong ^{[1
]}

Hu, Xiao-Qing ^{[1
]}

Yi, Shan ^{[1
]}

Ye, Jun ^{[1
]}

Kuang, Xiang-Jing ^{[1
]}

Wang, Yan ^{[1
]}

Zhang, Guang-Ming ^{[1
]}

Sun, Mao-Sheng ^{[1
]}

Wang, Yan-Xia ^{[2
]}

Hu, Zhong-Yu ^{[3
]}

Yang, Jing-Si ^{[1
]}

Li, Hong-Jun ^{[1
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Yunnan Key Lab Vaccine Res & Dev Severe Infect Dis, Inst Med Biol, 935 Jiaolinglu, Kunming 650118, Peoples R China

[2] Henan Prov Ctr Dis Control & Prevent, 105 Zhendong Xinqu Nongye Nanlu, Zhengzhou 450016, Peoples R China

[3] Natl Inst Food & Drug Control, 2 Tiantan Xili, Beijing 100050, Peoples R China

来源：

VACCINE | 2024年 / 42卷 / 19期

关键词：

Rotavirus; Rotavirus inactivated vaccine; Safety; Immunogenicity; 1ST; 2; YEARS; EFFICACY; INFANTS; GASTROENTERITIS; CHILDREN; ROTASHIELD; IMMUNITY; STRAIN; YUNNAN; LIFE;

D O I：

10.1016/j.vaccine.2024.05.014

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We conducted a phase I, randomized, double-blind, placebo-controlled trial including healthy adults in Sui County, Henan Province, China. Ninety-six adults were randomly assigned to one of three groups (high-dose, medium-dose, and low-dose) at a 3:1 ratio to receive one vaccine dose or placebo. Adverse events up to 28 days after each dose and serious adverse events up to 6 months after all doses were reported. Geometric mean titers and seroconversion rates were measured for anti-rotavirus neutralizing antibodies using microneutralization tests. The rates of total adverse events in the placebo group, low-dose group, medium-dose group, and high-dose group were 29.17 % (12.62 %-51.09 %), 12.50 % (2.66 %-32.36 %), 50.00 % (29.12 %-70.88 %), and 41.67 % (22.11 %-63.36 %), respectively, with no significant difference in the experimental groups compared with the placebo group. The results of the neutralizing antibody assay showed that in the adult group, the neutralizing antibody geometric mean titer at 28 days after full immunization in the low-dose group was 583.01 (95 % confidence interval [CI]: 447.12-760.20), that in the medium-dose group was 899.34 (95 % CI: 601.73-1344.14), and that in the high-dose group was 1055.24 (95 % CI: 876.28-1270.75). The GMT of serumspecific IgG at 28 days after full immunization in the low-dose group was 3444.26 (95 % CI: 2292.35-5175.02), that in the medium-dose group was 6888.55 (95 % CI: 4426.67-10719.6), and that in the high-dose group was 7511.99 (95 % CI: 3988.27-14149.0). The GMT of serum-specific IgA at 28 days after full immunization in the low-dose group was 2332.14 (95 % CI: 1538.82-3534.45), that in the medium-dose group was 4800.98 (95 % CI: 2986.64-7717.50), and that in the high-dose group was 3204.30 (95 % CI: 2175.66-4719.27). In terms of safety, adverse events were mainly Grades 1 and 2, indicating that the safety of the vaccine is within the acceptable range in the healthy adult population. Considering the GMT and positive transfer rate of neutralizing antibodies for the main immunogenicity endpoints in the experimental groups, it was initially observed that the high-dose group had higher levels of neutralizing antibodies than the medium- and low-dose groups in adults aged 18-49

引用

页码：4030 / 4039

页数：10

共 54 条

[1] Rotavirus vaccine roll-out [J].